An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. When Baby KJ was introduced to the world ...

RFK Jr.'s vaccine questions in Samoa, former Stanford president rebuts fraud allegations, and more health news from Morning ...

A newly acquired Novartis drug cut signs of inflammation. The test will be whether that can improve people's heart health.

A scramble to prepare for massive federal cuts across the health care system is hitting rural states like Maine particularly ...

The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam ...

Roivant's autoimmune drug approval, Cytokinetics reports full data for heart condition treatment, and more biotech news ...

Turkish regulators are investigating Teva Pharmaceutical for allegedly manipulating the patent system and disparaging rival ...

The FDA approved a life-extending treatment for advanced pancreatic cancer from Revolution Medicines that is the first to ...

AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a ...

WASHINGTON — After Pennsylvania health authorities announced that two unvaccinated people had died from measles-associated ...

Juul has received FDA clearance to sell an updated version of its e-cigarette, which includes an optional age-verification ...